Background The plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G insertion/deletion polymorphism has been associated with increased risk of myocardial infarction (MI) and decreased risk of cerebrovascular events. Whether these results apply to young women is not known.
Methods We genotyped 78 MI cases, 106 stroke cases and 385 age-matched controls from a population-based case–control study of MI and stroke in women < 45 years old.
Results The risk of MI was significantly decreased in carriers of the 4G allele compared with 5G/5G homozygotes, and the association persisted upon adjustment for other risk factors (age- and race-adjusted OR 0.50, 95% CI 0.29–0.85). Carrying the 4G allele was not associated with stroke, either overall or according to subtype. The association of this polymorphism with MI or stroke did not vary significantly by presence or absence of established cardiovascular risk factors, assessed on either an additive or multiplicative scale.
Conclusions These data suggest a decreased risk of MI among young women carrying the 4G allele of the PAI-1 4G/5G polymorphism. Although this result contrasts with those of previous studies of older adults and young men, it may highlight the influence of genetic factors on the development of MI within the context of particular hormonal or environmental influences.
Dalager-PedersenSRavnHBFalkE.Atherosclerosis and acute coronary events. Am J Cardiol1998; 82:37T–40T.
2.
NordtTKPeterKRuefJKublerWBodeC.Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease. Thromb Haemost1999; 82 (suppl 1):14–18.
3.
GebaraOCMittlemanMASutherlandPLipinskaIMatheneyTXuPAssociation between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation1995; 91:1952–1958.
4.
MargaglioneMCappucciGd'AddeddaMColaizzoDGiulianiNVecchioneGPAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: Relation to environmental and genetic determinants. Arterioscler Thromb Vasc Biol1998; 18:562–567.
5.
DawsonSJWimanBHamstenAGreenFHumphriesSHenneyAM.The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem1993; 268:10739–10745.
6.
ErikssonPKallinBvant HooftFMBavenholmPHamstenA.Allele-specific increase in basal transcription of the plasminogen- activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA1995; 92:1851–1855.
7.
Ossei-GerningNMansfieldMWSticklandMHWilsonIJGrantPJ.Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler Thromb Vasc Biol1997; 17:33–37.
8.
GardemannALohreJKatzNTillmannsHHehrleinFWHaberboschW.The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease. Thromb Haemost1999; 82:1121–1126.
9.
MansfieldMWSticklandMHGrantPJ.Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost1995; 74:1032–1034.
10.
YeSGreenFRScarabinPYNicaudVBaraLDawsonSJThe 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctus du Mycocarde. Thromb Haemost1995; 74:837–841.
11.
RidkerPMHennekensCHLindpaintnerKStampferMJMiletichJP.Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation1997; 95:59–62.
12.
DoggenCJBertinaRMCatsVMReitsmaPHRosendaalFR.The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction. Thromb Haemost1999; 82:115–120.
13.
JunkerRHeinrichJSchulteHTataruMKohlerESchonfeldRPlasminogen activator inhibitor-1 4G/5G-polymorphism and factor V Q506 mutation are not associated with myocardial infarction in young men. Blood Coagul Fibrinolysis1998; 9:597–602.
14.
SuganoTTsujiHMasudaHNakagawaKNishimuraHKasaharaTPlasminogen activator inhibitor-1 promoter 4G/5G genotype is not a risk factor for myocardial infarction in a Japanese population. Blood Coagul Fibrinolysis1998; 9:201–204.
15.
AndersonJLMuhlesteinJBHabashiJCarlquistJFBairTLElmerSPLack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction. J Am Coll Cardiol1999; 34:1778–1783.
16.
GranchaSEstellesATormoGFalcoCGilabertJEspanaFPlasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease. Thromb Haemost1999; 81:516–521.
17.
CattoAJCarterAMSticklandMBamfordJMDaviesJAGrantPJ.Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thromb Haemost1997; 77:730–734.
18.
RoestMvan der SchouwYTBangaJDTempelmanMJde GrootPGSixmaJJPlasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation2000; 101:67–70.
19.
EndlerGLalouschekWExnerMMitterbauerGHaringDMannhalterC.The 4G/4G genotype at nucleotide position −675 in the promoter region of the plasminogen activator inhibitor 1 (PAI-1) gene is less frequent in young patients with minor stroke than in controls. Br J Haematol2000; 110:469–471.
20.
NewbyDEWrightRALabinjohCLudlamCAFoxKABoonNAEndothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: A mechanism for arterial thrombosis and myocardial infarction. Circulation1999; 99:1411–1415.
21.
SiscovickDSSchwartzSMRosendaalFRPsatyBM.Thrombosis in the young: Effect of atherosclerotic risk factors on the risk of myocardial infarction associated with prothrombotic factors. Thromb Haemost1997; 78:7–12.
22.
RosendaalFRSiscovickDSSchwartzSMBeverlyRKPsatyBMLongstrethWTFactor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood1997; 89:2817–2821.
23.
RosendaalFRSiscovickDSSchwartzSMPsatyBMRaghunathanTEVosHL.A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood1997; 90:1747–1750.
24.
SchwartzSMSiscovickDSMalinowMRRosendaalFRBeverlyRKHessDLMyocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation1997; 96:412–417.
25.
SchwartzSMSiscovickDSLongstrethWTJrPsatyBMBeverlyRKRaghunathanTEUse of low-dose oral contraceptives and stroke in young women. Ann Intern Med1997; 127:596–603.
26.
FalkGAlmqvistANordenhemASvenssonHWimanB.Allele-specific PCR for detection of a sequence polymorphism in the promoter region of the plasminogen-activator inhibitor-1 (PAI-1) gene. Fibrinolysis1995; 9:170–174.
27.
RothmanKJ.Interaction between causes. In: RothmanKJ, editor. Modern epidemiology. Boston: Little, Brown, 1986; pp. 311–326.
28.
VaisanenSBHumphriesSELuongLAPenttilaIBouchardCRauramaaR.Regular exercise, plasminogen activator inhibitor-1 (PAI-1) activity and the 4G/5G promoter polymorphism in the PAI-1 gene. Thromb Haemost1999; 82:1117–1120.
29.
MannucciPMMariDMeratiGPeyvandiFTagliabueLSacchiEGene polymorphisms predicting high plasma levels of coagulation and fibrinolysis proteins. A study in centenarians. Arterioscler Thromb Vasc Biol1997; 17:755–759.
